磷酸西格列汀联合二甲双胍对2型糖尿病患者血糖控制及胰岛素抵抗的治疗效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (428 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Sitagliptin Phosphate combined with Metformin on the improvement of blood glucose control and insulin resistance in patients with type 2 diabetes mellitus, and to provide evidence for the diagnosis and treatment of patients. Methods Eighty patients with type 2 diabetes mellitus who were admitted to Fuyang Women’s and Children’s Hospital, Anhui Province from April 2019 to April 2020 were selected as the research subjects. They were divided into observation group and control group by random number table method, with 40 cases in each group. The control group was treated with Metformin and the observation group was treated with Sitagliptin Phosphate combined with Metformin. Both groups were treated for 12 weeks. The effects of treatment were compared between the two groups. The changes of fasting blood glucose (FBG), 2 h postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c) and fasting insulin (FINS) before and after treatment were recorded in the two groups, and the adverse reactions during treatment in the two groups were counted. Results The total effective rate of observation group was significantly higher than that of control group, the difference was statistically significant (P ＜ 0.05). After treatment, FBG, 2hPBG and HbA1c in the observation group were lower than those in the control group, with statistical significance (all P ＜ 0.05). FINS in observation group was higher than that in control group, and the difference was statistically significant (P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Sitagliptin Phosphate combined with Metformin has a definite effect on the treatment of type 2 diabetes mellitus, which can effectively improve blood glucose, improve the secretion function of pancreatic β cells, reduce insulin resistance, and has a high safety.

Key words： Type 2 diabetes mellitus Sitagliptin Phosphate Metformin Blood glucose Insulin resistance Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YUAN Ting

Cite this article:

YUAN Ting. Therapeutic effect of Sitagliptin Phosphate combined with Metformin on blood glucose control and insulin resistance in patients with type 2 diabetes mellitus[J]. 中国医药导报, 2021, 18(6): 91-94.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I6/91

[1] 干异，杨成会.西格列汀联合二甲双胍对2型糖尿病患者糖、脂代谢及胰岛素抵抗的影响[J].中国煤炭工业医学杂志，2017，20（12）：1442-1446.
[2] 李斐，曲震理.西格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床研究[J].中国临床药理学杂志，2018，34（5）：518-520，527.
[3] 刘阳，杨静，任毅，等.磷酸西格列汀联合二甲双胍治疗2型糖尿病的临床疗效观察[J].中西医结合心脑血管病杂志，2018，16（12）：1725-1727.
[4] Tsurutani Y，Nakai K，Inoue K，et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple me-tabolic variables in Japanese patients with type 2 diabetes A multicentre，randomized，prospective，open-label，active-controlled study [J]. Dia Edu，2018，20（11）：2675-2679.
[5] 周莉桢，郭杏花，郑仲萍.二甲双胍联合降糖药物对2型糖尿病病人血糖控制率、血糖相关指标及胰岛β细胞功能指标的影响[J].中西医结合心脑血管病杂志，2019，17（8）：1233-1235.
[6] 孙洁，李顺来，李曼.基础胰岛素联合西格列汀片对血糖控制及氧化应激及炎症反应的影响[J].海南医学院学报，2018，24（13）：1246-1249.
[7] 吴金婵，陈娟，冯光球.二甲双胍联合西格列汀或瑞格列奈治疗肥胖2型糖尿病患者的效果比较[J].中国医药，2019，14（5）：87-90.
[8] Temneanu OR，Trandafir LM，Purcarea MR. Type 2 diabetes mellitus in children and adolescents：a relatively new clinical problem within pediatric practice [J]. J Med Life，2016，9（3）：235-239.
[9] 韩秀平，孙涛，贺钰梅，等.磷酸西格列汀联合二甲双胍治疗初发2型糖尿病的临床效果[J].中国医药导报，2016， 13（12）：165-168.
[10] 陈赟，何瑶，马维青，等.西格列汀联合二甲双胍治疗腹型肥胖2型糖尿病的临床效果及安全性[J].中国医药，2018，13（4）：545-549.
[11] Esposito G，Cappetta D，Russo R，et al. Sitagliptin reduces inflammation，fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction [J]. Br J Pharmacol，2017，174（22）：4070-4086.
[12] 余进，陈曦.磷酸西格列汀对2型糖尿病合并非酒精性脂肪肝患者肝功能、胰岛素抵抗和BMI的影响[J].华南国防医学杂志，2019，33（1）：25-29.
[13] Mohan V，Ramu M，Poongothai S，et al. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study [J]. J Assoc Phy Ind，2019，67（10）：14-19.
[14] 郝姝，贾真，张渭涛，等.二甲双胍联合西格列汀对2型糖尿病患者氧化应激、胰岛素抵抗的影响[J].现代生物医学进展，2016，16（33）：6467-6469，6525.
[15] Takihata M，Terauchi Y. The efficacy and safety of luse-ogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus：a randomized controlled pilot study [J]. Expert Opin Pharmacother，2019，20（17）：2185-2194.
[16] 李霞，白小岗，刘欣齐，等.单用二甲双胍血糖控制不达标的老年2型糖尿病患者联合西格列汀治疗的临床疗效及安全性分析[J].空军医学杂志，2017，33（6）：384-387.
[17] 宋金方，张亮，林维娜，等.达格列净或西格列汀联合二甲双胍治疗2型糖尿病的疗效对比研究[J].实用药物与临床，2019，22（3）：253-255.
[18] Dai D，Mao Y，Jin H，et al. Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists：A meta-analysis [J]. Medicine（Baltimore），2019，98（36）：e17081.
[19] 常娟.西格列汀联合二甲双胍治疗2型糖尿病临床疗效、血糖指标及不良事件观察[J].检验医学与临床，2017， 14（z2）：353-355.
[20] 苑婕，薛媛，刘海艳.磷酸西格列汀联合二甲双胍治疗初发2型糖尿病的临床效果分析[J].中国医药科学，2020，10（15）：88-90.
[21] Kelleher JF，Madi AM，Gilvary GC，et al. Metformin Hydrochloride and Sitagliptin Phosphate Fixed-Dose Combination Product Prepared Using Melt Granulation Continuous Processing Technology [J]. AAPS PharmSciTech，2019，21（1）：23-25.
[22] 孙婷婷，郝伟，李明明，等.利格列汀片联合二甲双胍片治疗初诊2型糖尿病的临床研究[J].中国临床药理学杂志，2019，35（7）：633-636.
[23] 郝兆虎，邵海琳，黄霄，等.达格列净与西格列汀对胰岛素控制不佳的超重及肥胖2型糖尿病患者的疗效观察[J].中华糖尿病杂志，2019，11（9）：592-596.
[24] Goldenberg RM，Berard L. Adding prandial GLP-1 receptor agonists to basal insulin：a promising option for type 2 diabetes therapy [J]. Curr Med Res Opin，2018，34（1）：1-10.
[25] 邵珠林，杨杭妹，徐向进，等.沙格列汀与二甲双胍单药治疗对初发2型糖尿病患者骨代谢及体脂分布的影响[J].中华糖尿病杂志，2019，11（2）：114-119.
[26] 杨育生，刘振鹏.磷酸西格列汀联合二甲双胍治疗2型糖尿病的疗效分析[J].中国医药科学，2020，10（2）：51-53，142.
[27] George CM，Byun A，Howard-Thompson A. New injectable agents for the treatment of Type 2 diabetes part 1- injectable insulins [J]. Am J Med，2018，131（7）：752-754.